Clinical research design and statistical analysis for personalized medicine

Yasunori Sato, Kengo Nagashima, Chikuma Hamada

Research output: Contribution to journalReview article

Abstract

Interindividual variation in drug response among patients is well known and poses a serious problem in medicine. The variation could be due to multiple factors including those of the host (e. g., age, genetic and environmental factors) and disease (pathophysiological phenotypes). The complex interplay of these factors may influence pharmacodynamic responses such as adverse effects and efficacy, as well as pharmacokinetic manifestations. However, at present, few biomarkers can predict responders and non-responders, and those who might experience adverse reactions for the same medication and dose. In order to realize personalized medicine, rigorous development of biomarkers is required to identify new biomarkers that may change clinical practice. In this review, we first introduce how biomarkers may be used as targets and the difference between prognostic and predictive markers. Next, we focus on confirmatory clinical trial designs for biomarker development and introduce their application in actual studies. Finally, we introduce exploratory statistical screening techniques for detecting biomarkers in phase I and pharmacokinetics studies.

Original languageEnglish
Pages (from-to)291-300
Number of pages10
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume41
Issue number6
DOIs
Publication statusPublished - 2010 Nov 1
Externally publishedYes

Fingerprint

Precision Medicine
Research Design
Biomarkers
Pharmacokinetics
Medicine
Clinical Trials
Phenotype
Pharmaceutical Preparations

Keywords

  • Biomarker
  • Clinical trial design
  • Personalized medicine
  • Pharmacogenomics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical research design and statistical analysis for personalized medicine. / Sato, Yasunori; Nagashima, Kengo; Hamada, Chikuma.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 41, No. 6, 01.11.2010, p. 291-300.

Research output: Contribution to journalReview article

@article{789a6b215060478a9160dc257ad5369e,
title = "Clinical research design and statistical analysis for personalized medicine",
abstract = "Interindividual variation in drug response among patients is well known and poses a serious problem in medicine. The variation could be due to multiple factors including those of the host (e. g., age, genetic and environmental factors) and disease (pathophysiological phenotypes). The complex interplay of these factors may influence pharmacodynamic responses such as adverse effects and efficacy, as well as pharmacokinetic manifestations. However, at present, few biomarkers can predict responders and non-responders, and those who might experience adverse reactions for the same medication and dose. In order to realize personalized medicine, rigorous development of biomarkers is required to identify new biomarkers that may change clinical practice. In this review, we first introduce how biomarkers may be used as targets and the difference between prognostic and predictive markers. Next, we focus on confirmatory clinical trial designs for biomarker development and introduce their application in actual studies. Finally, we introduce exploratory statistical screening techniques for detecting biomarkers in phase I and pharmacokinetics studies.",
keywords = "Biomarker, Clinical trial design, Personalized medicine, Pharmacogenomics",
author = "Yasunori Sato and Kengo Nagashima and Chikuma Hamada",
year = "2010",
month = "11",
day = "1",
doi = "10.3999/jscpt.41.291",
language = "English",
volume = "41",
pages = "291--300",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "6",

}

TY - JOUR

T1 - Clinical research design and statistical analysis for personalized medicine

AU - Sato, Yasunori

AU - Nagashima, Kengo

AU - Hamada, Chikuma

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Interindividual variation in drug response among patients is well known and poses a serious problem in medicine. The variation could be due to multiple factors including those of the host (e. g., age, genetic and environmental factors) and disease (pathophysiological phenotypes). The complex interplay of these factors may influence pharmacodynamic responses such as adverse effects and efficacy, as well as pharmacokinetic manifestations. However, at present, few biomarkers can predict responders and non-responders, and those who might experience adverse reactions for the same medication and dose. In order to realize personalized medicine, rigorous development of biomarkers is required to identify new biomarkers that may change clinical practice. In this review, we first introduce how biomarkers may be used as targets and the difference between prognostic and predictive markers. Next, we focus on confirmatory clinical trial designs for biomarker development and introduce their application in actual studies. Finally, we introduce exploratory statistical screening techniques for detecting biomarkers in phase I and pharmacokinetics studies.

AB - Interindividual variation in drug response among patients is well known and poses a serious problem in medicine. The variation could be due to multiple factors including those of the host (e. g., age, genetic and environmental factors) and disease (pathophysiological phenotypes). The complex interplay of these factors may influence pharmacodynamic responses such as adverse effects and efficacy, as well as pharmacokinetic manifestations. However, at present, few biomarkers can predict responders and non-responders, and those who might experience adverse reactions for the same medication and dose. In order to realize personalized medicine, rigorous development of biomarkers is required to identify new biomarkers that may change clinical practice. In this review, we first introduce how biomarkers may be used as targets and the difference between prognostic and predictive markers. Next, we focus on confirmatory clinical trial designs for biomarker development and introduce their application in actual studies. Finally, we introduce exploratory statistical screening techniques for detecting biomarkers in phase I and pharmacokinetics studies.

KW - Biomarker

KW - Clinical trial design

KW - Personalized medicine

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=79551615856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551615856&partnerID=8YFLogxK

U2 - 10.3999/jscpt.41.291

DO - 10.3999/jscpt.41.291

M3 - Review article

AN - SCOPUS:79551615856

VL - 41

SP - 291

EP - 300

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 6

ER -